Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing heart failure with immunomodulatory agents.

K A Lisman1, S J Stetson, M M Koerner

  • 1DeBakey Heart Center, Methodist Hospital, Winters Center for Heart Failure Research, Gene and Judy Campbell Laboratory for Transplant Research, Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Texas, USA.

Cardiology Clinics
|November 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cumulative steroid dose in hospitalized patients and COVID-19-associated pulmonary aspergillosis.

The Journal of hospital infection·2023
Same author

Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score.

Pulmonology·2021
Same author

Extracorporeal Membrane Oxygenation (ECMO): An Option for Cardiac Reccovery from Advanced Cardiogenic Shock.

The heart surgery forum·2017
Same author

Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.

The heart surgery forum·2017
Same author

Tumor necrosis factor-α in the failing human heart: Does it play a role in disease progression?

Zeitschrift fur Kardiologie·2016
Same author

Cardiac responses to β-adrenoceptor stimulation is partly dependent on mitochondrial calcium uniporter activity.

British journal of pharmacology·2014

Immune activation contributes to heart failure progression, but past treatments have failed. Ongoing trials, like one using Etanercept for symptomatic heart failure, may reveal new therapeutic strategies for this condition.

Area of Science:

  • Cardiology
  • Immunology
  • Translational Medicine

Background:

  • Accumulating evidence suggests immune activation plays a role in heart failure progression.
  • Despite clinical interest, previous immunomodulatory interventions for heart failure have not yielded successful outcomes.

Purpose of the Study:

  • To explore the role of immune activation in heart failure.
  • To evaluate the potential of novel immunotherapeutic strategies for heart failure management.

Main Methods:

  • Review of existing clinical trials and evidence regarding immune activation in heart failure.
  • Highlighting the ongoing Etanercept trial in symptomatic heart failure patients as a key study.
  • Emphasis on the need for randomized clinical trials to define therapeutic efficacy.

Related Experiment Videos

Main Results:

  • No immunotherapy trials have definitively proven useful for heart failure mortality to date.
  • A significant ongoing clinical trial is investigating Etanercept's effect on mortality in symptomatic heart failure.

Conclusions:

  • Inflammation is increasingly recognized as a critical pathway in heart failure progression.
  • Future research and randomized clinical trials are essential to determine the effectiveness of specific or non-specific immunotherapies for heart failure.